Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Young Adults Face Tough Time Getting Insurance
Young adults are facing tough times with limited job prospects and no health insurance. The Associated Press reports on recent college graduate Emily Weinstein as being representative of the many young uninsured Americans: "Like millions of other uninsured adults in their 20s, Weinstein is watching Congress as it advances legislation to overhaul health care. The recession has deepened young adults" career struggles. It has also sharpened their interest in health insurance. Already the least likely of any age group to have coverage, adults in their 20s face brutal job searches and more time uninsured because of the recession. Nearly 30 percent, 13.2 million, were uninsured in 2007, according to the Commonwealth Fund, a New York-based research center. Many young adults work entry-level jobs without insurance and, despite new laws in some states, they"re eventually too old to stay on their parents" policies."
generic viagra online
New Study Evaluates Role Of Clinic Environment On Physician Job Satisfaction
Adverse work conditions may be to blame for the decline in the number of primary care physicians nationwide, according to a study published in the latest issue of the Annals of Internal Medicine.
News of the day
Unexpected Bacterial Diversity Found On Human Skin
The health of our skin - one of the body"s first lines of defense against illness and injury - depends upon the delicate balance between our own cells and the millions of bacteria and other one-celled microbes that live on its surface. To better understand this balance, National Institutes of Health researchers have set out to explore the skin"s microbiome, which is all of the DNA, or genomes, of all of the microbes that inhabit human skin. Their initial analysis, published in the journal Science, reveals that our skin is home to a much wider array of bacteria than previously thought.
Nutrition

Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer

A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from Mayo Clinic indicates. At the annual meeting of the American Society of Clinical Oncology (ASCO), Mayo investigators report that cancer in about two-thirds of 37 patients with aggressive differentiated thyroid cancer treated with the drug pazopanib either stopped growing, or quickly shrank. The patient responses seen to date are promising, the researchers say, because all patients had fast-growing cancers that had spread to their lungs, with half involving lymph nodes and 39 percent also involving bones. "The benefits were striking in many patients to a degree we have not previously seen in thyroid cancer in response to other therapies, including the standard treatment of radioiodine," says Keith Bible, M.D., Ph.D., a medical oncologist and researcher who led the multicenter clinical trial funded by the National Cancer Institute. Most of the patients treated were enrolled at the Mayo Clinic campuses in Minnesota and Florida. Approximately one-third of patients achieved sustained and dramatic benefit from pazopanib, while another one-third experienced stabilization of their cancer or some tumor shrinkage. The remaining one-third of patients did not benefit from the drug. The agent was also well tolerated by the majority of patients, Dr. Bible adds. What is not yet known, however, is the drug"s effect on overall survival. "We need more time to establish that definitively," says Dr. Bible. "The trial has been going on for just over a year, and some of our patients are still maintaining a response, while others have not been in the study long enough for us to confirm duration of response." He notes that of the 37 original trial participants, two have died - one from cancer progression and another from other causes. The National Cancer Institute estimated that 37,340 new cases of thyroid cancer would be diagnosed in 2008, with 1,590 deaths from the cancer. The cancer is much more common in women; it is the seventh most common cancer in women in the U.S. The occurrence of thyroid cancer has recently been rising. Most thyroid cancers are of two major "differentiated" types - papillary thyroid cancer (the most common, accounting for 75 percent of cases) and follicular thyroid cancer (15 percent). Fortunately, most patients with thyroid cancer respond well to surgery and to follow-up treatment with radioiodine; even if the cancer recurs and spreads, the disease progresses slowly in most patients, Dr. Bible says. "Many patients do well for a long time without the need of additional therapy," he says. However, about 5 percent of these patients experience rapidly progressing life-threatening disease that is insensitive to radioiodine and other treatment approaches. "Until only recently, we have not had any effective therapies for such patients." Pazopanib is an experimental agent that is also being studied in advanced kidney, ovarian and other cancers. The drug, administered in pill form, targets proteins involved in angiogenesis, the growth of new blood vessels that has a critical role in the growth and spread of tumors. The proteins that pazopanib targets include vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-kit and Ret. Mayo investigators are also leading clinical trials to test pazopanib in two other thyroid cancer subtypes -medullary, which does not respond to radioiodine, and anaplastic, the most aggressive subtype. Dr. Bible says plans are also under way to test pazopanib in a larger, controlled and randomized clinical trial of patients with advanced differentiated thyroid cancer. Researchers want to more accurately assess benefits and risks. Karl Oestreich Mayo Clinic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009